Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single Center, Phase II Clinical Study of PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer

NCT06792162 is registered in ClinicalTrials.gov with Peking University Third Hospital as lead sponsor.

NCT NCT06792162
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06792162 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single Center, Phase II Clinical Study of PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer
Lead sponsor
Peking University Third Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
April 20, 2023
Completion date
April 30, 2027
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer